An experiment conducted on CD44+ prostate cancer stem cells provided relevant information that apigenin co-administrated with cisplatin stimulated the therapeutic effects of cisplatin by inducing a series of modulatory effects on the expression of essential proteins and enzymes [188]. This evidence concerns the gene CD44 and Familial prostate cancer.